VJOncology is committed to improving our service to you

ESMO 2019 | Preliminary findings in mCRPC for fractionated dose 177Lu-PSMA-617

VJOncology is committed to improving our service to you

Scott Tagawa

Scott Tagawa, MD, MS, Weill Cornell Medicine, New York, NY, discusses the initial findings of the trial of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC; NCT03042468). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter